Experimental diabetes drug lixisenatide helped improve glycemic control during tests when it was used in conjunction with basal insulin, French pharmaceutical company Sanofi-aventis has reported.
The firm’s Asian research also found that there were no safety concerns with lixisenatide in patients with type 2 diabetes. Positive results from the study have been unveiled by Sanofi ahead of a seminar for investors on diabetes.
Sanofi already offers insulin product Lantus in the diabetes market but has set up a specialist research unit to increase its presence in the market. Diabetes is a disease which is becoming more common across the globe as the level of overweight people continues to increase.
A GLP-1 class of drug, Lantus works by stimulating the release of insulin when glucose levels become too high. It would be up against Novo Nordisk’s Victoza and Amylin and Eli Lilly’s Byetta if it is given marketing approval.
Sanofi plans to hold a seminar for investors on diabetes and oncology later on Thursday.
Copyright Press Association 2010